Medical/Pharmaceuticals
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...
2025-10-31 21:00
2085
Bio Farma Indonesia Leads Global Vaccine Manufacturers as Host of the 26th DCVMN AGM in Bali
BALI, Indonesia, Oct. 31, 2025 /PRNewswire/ -- Bali, October 29, 2025, Indonesia , throughBio Farma, is hosting the 26th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers Network (DCVMN) inBali on October 29–31, 2025. The forum brings together vaccine manufacturers, ...
2025-10-31 20:01
2463
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku,Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the in...
2025-10-31 20:00
1524
Elevaris Medical Devices Names New Chief Engineering and Operations Officer
BOSTON, Oct. 31, 2025 /PRNewswire/ -- Elevaris Medical Devices, a Contract
Development and Manufacturing Organization for industry-leading multi-national
healthcare companies, announced the appointment of its new Chief Engineering
and Operations Officer,Salvador Montes.
2025-10-31 20:00
1170
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
FRANKFURT, Germany, Oct. 31, 2025 /PRNewswire/ -- From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international commercialization solutions to partners from glo...
2025-10-31 19:50
1622
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with R...
2025-10-31 17:38
1171
Xinhua Silk Road: Chinese biz leaders hold talks to explore cultural inheritance, innovation
BEIJING, Oct. 31, 2025 /PRNewswire/ -- On Tuesday, an in-depth talk between board chairmen of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) and Kweichow Moutai Group highlighted joint effort to promote inheritance and innovation of traditional Chinese culture. After discussi...
2025-10-31 16:15
875
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™"
TAMPA, Fla., Oct. 31, 2025 /PRNewswire/ -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focu...
2025-10-31 08:30
1050
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
* NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise inGreater China and other Asian markets * Nov...
2025-10-30 16:15
1067
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...
2025-10-30 15:28
1032
United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the compa...
2025-10-30 13:58
878
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 inGreater China, Singapore, South Korea, and certain Southeast Asian countries. * Under the assigned exclusive license, Everest Medicines will make an upfront payment ofUS$7 million (equivalen...
2025-10-30 11:05
1253
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
* Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. * The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported...
2025-10-30 09:15
1220
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announcedthe initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experi...
2025-10-30 09:00
1223
Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and c...
2025-10-30 09:00
1043
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared t...
2025-10-30 08:10
1181
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and P...
2025-10-29 23:21
1387
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
* New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide * Strategy centers on broadening access to global capital and innovation through a plannedHong Kong initial public offering (IPO), and holding...
2025-10-29 23:15
2677
Suvoda launches unified patient app to reduce logistical challenges for clinical trial participants
CONSHOHOCKEN, Pa., Oct. 29, 2025 /PRNewswire/ -- Suvoda
2025-10-29 21:15
1119
Study Finds ELISAs in Milk Samples Less Reliable for Johne's Disease Detection -- $198M in Dairy Losses Underscore Need for More Accurate Milk Testing
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance and profitability CARLSBAD, Calif., Oct. 29, 2025 /PRNewswire/ -- Pictor Holdings Inc. today announced new peer-reviewed dat...
2025-10-29 21:00
1134
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00